Moberg Pharma AB (FRA:MB8) Notes Receivable: €0.00 Mil (As of Mar. 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
59 GF Score
Price €0.80
GF Value €1.07
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Notes Receivable?

Moberg Pharma AB FRA:MB8 +0.50% 59 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.07. The stock has 1 warning sign investors should review.

Moberg Pharma AB's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

Moberg Pharma AB Notes Receivable Related Terms

Moberg Pharma AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Notes Receivable Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:MB8
59GF Score
Moberg Pharma AB FRA:MB8
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Moberg Pharma AB (FRA:MB8) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's Notes Receivable too high?
Moberg Pharma AB's current Notes Receivable is €0.00 Mil. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Notes Receivable compare to ZTS and UTHR?
Moberg Pharma AB's Notes Receivable of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Notes Receivable of €0.00 Mil. The stock's GF Value™ is €1.07, compared to a current price of €0.80 — trading 24.9% below its estimated fair value. The current Notes Receivable is €0.00 Mil. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.80 is trading 24.9% below its estimated GF Value™ of €1.07.

Key valuation signals for FRA:MB8:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €1.07 vs. price of €0.80 (24.9% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for FRA:MB8

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€1.07
GF Value